United Therapeutics 2025 Q3 Earnings Record Net Income Growth of 9.6%

United Therapeutics (UTHR) reported fiscal 2025 Q3 results on October 30, 2025. The biotechnology company exceeded EPS expectations while revenue grew 6.8% year-over-year, though it fell short of forecasts.

Revenue

Total revenue reached $799.50 million in Q3 2025, reflecting 6.8% growth compared to $748.90 million in Q3 2024. Tyvaso led with $478 million in sales, followed by Orenitram at $131.10 million and Remodulin at $125.90 million. Unituxin contributed $47.90 million, while Adcirca and other products accounted for $9.70 million and $6.90 million, respectively. The performance highlights sustained demand for its pulmonary hypertension treatments.

Earnings/Net Income

Earnings per share (EPS) rose 11.5% to $7.73, outpacing the $6.93 recorded in Q3 2024. Net income surged 9.6% to $338.70 million, marking a record high for the quarter and reflecting improved profitability. This EPS growth underscores the company’s operational efficiency and pricing power.

Price Action

Shares of UTHR gained 0.50% on the latest trading day, 6.41% over the past week, and 8.19% month-to-date. The stock’s rally followed positive clinical trial results and strong EPS performance.

Post-Earnings Price Action Review

The company’s recent results highlight robust financial performance and market confidence. However, historical data on revenue beats remains insufficient for backtesting a strategy based on revenue surprises. While UTHR’s 7% YoY revenue growth in Q3 2025 was driven by Tyvaso DPI and Orenitram, the stock’s 11.7% post-earnings surge was primarily attributed to EPS beats and promising clinical outcomes. Long-term growth potential remains evident, though data gaps in revenue beat/miss indicators limit strategic validation. <visualization dataurl="https://cdn.ainvest.com/news/visual/visual_components/viz_axg4u1a2.json"></visualization>

CEO Commentary

Laura H. Stokke, President and CEO, emphasized operational execution and innovation during the earnings call. She highlighted Tyvaso DPI’s role in driving dosing behavior shifts and the successful enrollment of Phase III trials for pulmonary fibrosis. Stokke expressed optimism about the TETON 2 study’s potential to expand market opportunities, while acknowledging supply chain challenges. The tone was cautiously optimistic, balancing growth momentum with strategic prudence.

Guidance

UTHR provided forward-looking guidance aligned with current performance trends. The company expects to maintain its $4 billion revenue run rate by 2027, driven by product launches like the 80-microgram Tyvaso DPI cartridge and RemunityPRO pump. No material revisions to revenue or EPS estimates were announced, with management reiterating confidence in its long-term growth trajectory.

Additional News

1. Product Launches: United Therapeutics launched the 80-microgram Tyvaso DPI cartridge in Q3, enhancing patient convenience and market competitiveness. The new RemunityPRO pump for Remodulin also debuted, signaling innovation in delivery systems.

2. Clinical Milestones: The TETON 2 study demonstrated Tyvaso’s efficacy in idiopathic pulmonary fibrosis, with unblinded results showing improved lung function. This positions UTHR to expand into new therapeutic areas.

3. Market Access: The company secured favorable coverage decisions with major payers for Tyvaso DPI, reinforcing its market positioning and reimbursement capabilities. Analysts remain optimistic about long-term revenue potential despite near-term competition concerns.

<img src="https://cdn.ainvest.com/aigc/hxcmp/images/compress-aime_generated_1761864790216.jpg.png" style="max-width:100%;">